Replies to post #88199 on Biotech Values

[drbio45]

look for companies that will be able to produce apo milano efficiently and not owe pfizer anything

[DewDiligence]

MDCO:

Do you believe that the likelihood of generic competition for Angiomax is already priced into the stock valuation, or is it not priced in because it's not a certainty yet?

It’s already priced in, IMO. The stock has been in a downward trend ever since it became clear that MDCO was not going to be able to extend the US patent:

[DewDiligence]

MDCO engages OctoPlus for process work on ApoA1 Milano:

http://finance.yahoo.com/news/OctoPlus-Signs-Drug-iw-3824399795.html?x=0&.v=1

p.s. OctoPlus developed the sustained-release carrier for Biolex’s Locteron, although OctoPlus is no longer directly involved in that program.

[DewDiligence]

Remember Recothrom…the gem from Zymogenetics? Well, BMY just offloaded it to MDCO, a company who seems willing to take—and pay good money for—whatever products and product candidates Big Pharma doesn’t want:

http://finance.yahoo.com/news/medicines-company-bristol-myers-squibb-120000013.html

The Medicines Company will pay Bristol-Myers Squibb an upfront collaboration payment of $105 million and an upfront option fee of $10 million. The Medicines Company has also agreed to pay Bristol-Myers Squibb a tiered royalty on annual net revenues of Recothrom during the two-year collaboration term. Bristol-Myers Squibb will retain responsibility for the manufacturing of Recothrom and will be The Medicine Company's exclusive supplier of Recothrom during the term of the agreement. The option enables The Medicines Company to acquire the Recothrom assets for a purchase price based on average net sales during the two-year collaboration term.

[DewDiligence]

MDCO -10%/AH on unexceptional interim analysis in MILANO-PILOT study of Apo-A1-Milano:

http://finance.yahoo.com/news/medicines-company-provides-dyslipidemia-programs-203000383.html

A planned, interim analysis of the first 40 randomized patients completing treatment in the MILANO-PILOT study of MDCO-216 has been reviewed by the Independent Data Monitoring Committee (IDM Committee). Based on the protocol and pre-defined criteria in its Charter, the IDM Committee has reported the 40-patient data to the Company in summary form and recommended that the MILANO-PILOT study continue. ]b\The pre-defined, upper statistical boundary for efficacy, which permits early termination of the study by the Company, was not met and, given the limited number of patients included in the first interim analysis, the summary data received by the Company from the IDM Committee are, at this time, inconclusive.

The Company has completed enrollment of the planned 120 patients and expects that results from the MILANO-PILOT study will be presented by its principal investigator, Dr. Steven Nissen of the Cleveland Clinic, in the Late-Breaking Clinical Trial Session at the American Heart Association (AHA) Scientific Sessions 2016 on November 15, 2016 in New Orleans.

The PR says that interim data from the PCSK9 ORION-1 trial will be presented at the same conference.

p.s. A perusal of this thread will show just how slow the clinical development of APo-A-1-Milano has been.